We will use 18F-FDG PET/CT myocardial metabolic imaging to observe changes in cardiac energy metabolism after SGLT2 inhibitor administration and further validate the therapeutic mechanisms of SGLT2 inhibitors in HF through pathological sections, Western blot (WB), and PCR assays. This evidence concerns the gene SLC5A2 and hydrops fetalis.